Lin Anqi, Che Chang, Jiang Aimin, Qi Chang, Glaviano Antonino, Zhao Zhijie, Zhang Zhirou, Liu Zaoqu, Zhou Ziyao, Cheng Quan, Yuan Shuofeng, Luo Peng
Donghai County People's Hospital (Affiliated Kangda College of Nanjing Medical University); Department of Oncology, Zhujiang Hospital, Southern Medical University, Lianyungang, 222000, China.
Xinling College, Nantong University, Nantong, Jiangsu, 226000, China.
Adv Sci (Weinh). 2025 Sep;12(33):e07764. doi: 10.1002/advs.202507764. Epub 2025 Aug 7.
Targeted drug design and development, as a core area of modern pharmaceutical research, critically depends on the assessment of protein site druggability as a fundamental component. This review systematically examines the latest research progress and application prospects of drug synergy and antagonism prediction methods that integrate protein three-dimensional spatial structure with artificial intelligence (AI) technologies. This review showcases the molecular biological mechanisms of drug synergism vs antagonism mediated by transcription factors, signal pathway regulation, and membrane transport proteins, and subsequently delves into the molecular structural basis of protein-drug interactions, including precise identification methods for drug binding sites, optimization strategies for molecular docking techniques, and the mechanisms and structural characteristics of multi-target drugs. The review systematically evaluates the practical application progress of AI technologies, especially machine learning and deep learning algorithms, in predicting drug synergy-antagonism effects, as well as the methodological approaches for constructing and evaluating the performance of AI prediction models that integrate multi-source biological data. These research findings provide a solid theoretical foundation for the precision treatment of cancer, infectious diseases, and metabolic disorders, with significant clinical and translational implications for advancing personalized medicine strategies in clinical practice and facilitating the rational design and development of novel multi-target drugs.
靶向药物设计与开发作为现代药物研究的核心领域,关键取决于对蛋白质位点可成药性的评估,这是一个基本组成部分。本综述系统地研究了将蛋白质三维空间结构与人工智能(AI)技术相结合的药物协同与拮抗预测方法的最新研究进展和应用前景。本综述展示了由转录因子、信号通路调控和膜转运蛋白介导的药物协同与拮抗的分子生物学机制,随后深入探讨了蛋白质-药物相互作用的分子结构基础,包括药物结合位点的精确识别方法、分子对接技术的优化策略以及多靶点药物的作用机制和结构特征。该综述系统地评估了人工智能技术,特别是机器学习和深度学习算法,在预测药物协同-拮抗作用方面的实际应用进展,以及构建和评估整合多源生物数据的人工智能预测模型性能的方法。这些研究结果为癌症、传染病和代谢紊乱的精准治疗提供了坚实的理论基础,对推进临床实践中的个性化医疗策略以及促进新型多靶点药物的合理设计与开发具有重要的临床和转化意义。